EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023 Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique...
EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress Company Unveils EVOLVE-105 Program, A Best-in-Class...
Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular Platform Being Leveraged to Advance Broad Pipeline of First-in-Category Costimulatory T Cell Engager Immunotherapies...
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Presentation Highlights CD2 as an Optimal Costimulatory Target; Demonstrates Durable in vivo Anti-Tumor Efficacy with EVOLVE ...
EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Poster Presentations Scheduled for American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and...
Over 30 Years of Leadership in Drug Discovery and Development, Translational Sciences and Biomarker Research in Immunology, Inflammatory Diseases and Tissue Fibrosis in Biopharma BRANFORD, CT – July 7, 2022 – EvolveImmune Therapeutics, an immuno-oncology company...
BRANFORD, CONN., April 29, 2021 — EvolveImmune Therapeutics, Inc., an emerging, privately held immunotherapy platform company, is pleased to announce that Ian Taylor, PhD has joined its board of directors. Dr. Taylor is a veteran biopharma executive who brings...
New Haven Biz highlighted the opening of EvolveImmune’s new headquarters in Branford, CT. Fully story at New Haven Biz.
Community leaders and team members gathered on October 22 to celebrate the opening of EvolveImmune’s new 9,000 square foot lab and office complex located in the Business Park Drive biotech cluster. Stephen Bloch, MD, Co-Founder and CEO made remarks along with the...